Saturday, November 15, 2025 9:42:58 AM
Lou Smith 🍀
@smith348572
Here is the most logical, evidence-based explanation for why market makers are keeping $NWBO share price extremely low and why this behavior is the opposite of normal market dynamics.
✅ The #1
Most Logical Reason: They Cannot Allow the Price to Rise Before Approval
This is the core reasoning that explains EVERYTHING.
If $NWBO has (imho):
•2B+ synthetic / naked short shares
•MHRA approval appears almost certain, with a 95% probability
then any significant rise in the price before the approval would trigger:
? Margin calls
? Buy-ins
? Collateral requirements jumping
? A forced short squeeze BEFORE the news
This would be catastrophic before they even get to the real danger: approval.
They must keep the price flat or lower to survive until the announcement.
✅ Reason #2
They need liquidity to escape if the worst happens
If approval arrives:
MM’s and hedge funds with synthetic shorts will need:
•massive volume
•massive retail/institutional buying
•massive price movement
to cover or partially cover.
BUT they cannot create that volume now.
So the goal is:
Keep the stock boring, flat, and unattractive.
Avoid volume.
Avoid buyers.
Because if big money steps in early, it steals the liquidity needed for them to escape later.
✅ Reason #3
They are avoiding “price discovery” before the approval
Remember this:
$NWBO is not trading based on its company value.
It trades based on short liabilities.
If price discovery happened today, the stock would instantly price in:
•UK approval probability
•GBM market
•Sawston’s MIA
•Flaskworks
•the lawsuit
•institutional entry
•partnership potential
•global regulatory follow-on approvals
Basic biotech math says NWBO’s pre-approval fair value is $2–$4.
But if the price rises now real price discovery = margin calls = forced covering.
So they prevent price discovery by:
•spoof walls
•dark pool volume
•hit pieces
•walking the bid
•grinding charts to discourage buyers
✅ Reason #4
They are defending a “synthetic short pyramid”
In a synthetic short structure, each additional synthetic share requires another layer of hedging.
If the stock rises:
•the hedges explode in cost,
•the options offsets become invalid,
•the synthetic chain collapses.
This creates a pyramid structure that must stay stable until the binary event (approval).
2:47 PM · Nov 15, 2025
·
277
Views
@smith348572
Here is the most logical, evidence-based explanation for why market makers are keeping $NWBO share price extremely low and why this behavior is the opposite of normal market dynamics.
✅ The #1
Most Logical Reason: They Cannot Allow the Price to Rise Before Approval
This is the core reasoning that explains EVERYTHING.
If $NWBO has (imho):
•2B+ synthetic / naked short shares
•MHRA approval appears almost certain, with a 95% probability
then any significant rise in the price before the approval would trigger:
? Margin calls
? Buy-ins
? Collateral requirements jumping
? A forced short squeeze BEFORE the news
This would be catastrophic before they even get to the real danger: approval.
They must keep the price flat or lower to survive until the announcement.
✅ Reason #2
They need liquidity to escape if the worst happens
If approval arrives:
MM’s and hedge funds with synthetic shorts will need:
•massive volume
•massive retail/institutional buying
•massive price movement
to cover or partially cover.
BUT they cannot create that volume now.
So the goal is:
Keep the stock boring, flat, and unattractive.
Avoid volume.
Avoid buyers.
Because if big money steps in early, it steals the liquidity needed for them to escape later.
✅ Reason #3
They are avoiding “price discovery” before the approval
Remember this:
$NWBO is not trading based on its company value.
It trades based on short liabilities.
If price discovery happened today, the stock would instantly price in:
•UK approval probability
•GBM market
•Sawston’s MIA
•Flaskworks
•the lawsuit
•institutional entry
•partnership potential
•global regulatory follow-on approvals
Basic biotech math says NWBO’s pre-approval fair value is $2–$4.
But if the price rises now real price discovery = margin calls = forced covering.
So they prevent price discovery by:
•spoof walls
•dark pool volume
•hit pieces
•walking the bid
•grinding charts to discourage buyers
✅ Reason #4
They are defending a “synthetic short pyramid”
In a synthetic short structure, each additional synthetic share requires another layer of hedging.
If the stock rises:
•the hedges explode in cost,
•the options offsets become invalid,
•the synthetic chain collapses.
This creates a pyramid structure that must stay stable until the binary event (approval).
2:47 PM · Nov 15, 2025
·
277
Views
Here is the most logical, evidence-based explanation for why market makers are keeping $NWBO share price extremely low and why this behavior is the opposite of normal market dynamics.
— Lou Smith 🍀 (@smith348572) November 15, 2025
âś… The #1
Most Logical Reason: They Cannot Allow the Price to Rise Before Approval
This is…
Bullish
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
